Literature DB >> 19779692

[Cancer pain therapy].

F Nauck1.   

Abstract

Pain belongs to the most prevalent symptoms that require patients with urological tumours to seek medical help. The treatment of cancer pain requires standardized guidelines that are best reflected by the WHO's three-step ladder of cancer pain relief. This implies an individualized approach, a detailed history taking of underlying pain and thorough clinical examination, as well as a consistent and forceful therapy of constant and breakthrough pain episodes, using pharmacological substances and non-pharmacological techniques. This requires the choice of the correct drug, an application "by the clock", an individualized dose titration, and the use of co-analgesics. For constant "background" pain, slow release substances are needed, whilst fast acting pain medication is given on demand for breakthrough pain episodes. Besides symptomatic analgesic therapy, cancer pain therapy may also comprise tumor specific treatment modalities, whenever appropriate and requested by the patient. This comprises radiation therapy, e.g. for bone or soft tissue processes or brain metastases, as well as radionuclide techniques, surgical procedures, chemotherapy, new substances or antihormonal therapy. Furthermore, pain is considered a multimodal experience that requires the consideration of psychical and social factors. This chapter describes the different facets of cancer pain, its epidemiology, pathophysiology, diagnostics and therapeutic principles.

Entities:  

Mesh:

Year:  2009        PMID: 19779692     DOI: 10.1007/s00120-009-2038-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  19 in total

Review 1.  Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care.

Authors:  Sebastiano Mercadante; Lukas Radbruch; Augusto Caraceni; Nathan Cherny; Stein Kaasa; Friedemann Nauck; Carla Ripamonti; Franco De Conno
Journal:  Cancer       Date:  2002-02-01       Impact factor: 6.860

Review 2.  Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms.

Authors:  Kristina B Svendsen; Steen Andersen; Sigurdur Arnason; Staffan Arnér; Harald Breivik; Tarja Heiskanen; Eija Kalso; Ulf E Kongsgaard; Per Sjogren; Peter Strang; Flemming W Bach; Troels S Jensen
Journal:  Eur J Pain       Date:  2005-04       Impact factor: 3.931

3.  Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice.

Authors:  G Zeppetella; C A O'Doherty; S Collins
Journal:  J Pain Symptom Manage       Date:  2000-08       Impact factor: 3.612

4.  Breakthrough pain: definition, prevalence and characteristics.

Authors:  Russell K Portenoy; Neil A Hagen
Journal:  Pain       Date:  1990-06       Impact factor: 6.961

5.  An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain.

Authors:  A Caraceni; R K Portenoy
Journal:  Pain       Date:  1999-09       Impact factor: 6.961

Review 6.  Pain assessment: global use of the Brief Pain Inventory.

Authors:  C S Cleeland; K M Ryan
Journal:  Ann Acad Med Singapore       Date:  1994-03       Impact factor: 2.473

7.  [Morphine and alternative opioids in cancer pain: the EAPC recommendations].

Authors:  L Radbruch; F Nauck
Journal:  Schmerz       Date:  2002-06       Impact factor: 1.107

Review 8.  Clinical pharmacokinetics of morphine.

Authors:  Ralph A Lugo; Steven E Kern
Journal:  J Pain Palliat Care Pharmacother       Date:  2002

Review 9.  Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany.

Authors:  Lukas Radbruch; Frank Elsner
Journal:  Keio J Med       Date:  2004-03

10.  [What do we know about the prevalence of pain caused by malignancy?].

Authors:  E Heidemann
Journal:  Schmerz       Date:  1999-08-19       Impact factor: 1.107

View more
  1 in total

Review 1.  [Pain management in urology].

Authors:  A Zimmer; F Greul; W Meißner
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.